Affiliation:
1. Department of Endocrinology, Javeriana University School of Medicine and San Ignacio University Hospital, Bogota, Colombia
2. Diabetes and Metabolism Department, Favaloro Foundation, University Hospital, Buenos Aires, Argentina
Abstract
Background:
Diabetes is a chronic disease with high complexity that demands strategic
medical care with a multifactorial risk-reduction approach. Over the past decade, the treatment of
type 2 diabetes mellitus (T2DM) has entirely changed. One of the paradigm changes has been the
arrival of new drugs that reduce cardiovascular risk beyond the reduction of A1C.
Objective:
Sodium-glucose cotransporter 2 (SGLT2i) and glucagon-like peptide-1 receptor agonist
(GLP-1RA) are two groups of antidiabetics drugs, which have demonstrated superiority compared
to placebo for major cardiovascular events (MACE).
Methods:
We update and discuss their impact on MACE expressed as relative risk (HR hazard ratio)
and as the number needed to treat (NNT) to avoid one cardiovascular event in 5 years. We include
the publications of the last 10 years.
Results:
Empagliflozin, Canagliflozin and Dapagliflozin present an HR for MACE of 0.86, 0.86,
0.86 and an NNT of 38, 44, and 33, respectively (Dapagliflozin in secondary prevention). Regarding
HHF (Hospitalization for Heart Failure), the HR was 0.65, 0.67, 0.73 and NNT was 44, 62, and
98, respectively. Lixisenatide, Exenatide, Liragutide, Semaglutide, Albiglutide and Dulaglutide presented
for MACE an HR of 1.02, 0.91, 0.87, 0.74, 0.78, 0.88, respectively. There was no increase
in the risk of HHF, but there was no benefit either.
Conclusion:
Cardiovascular benefits of the GLP-1RA and the SGLT2i are clinically significant. A
number needed to treat under 50 is required to avoid one MACE in five years. These benefits have
led to important changes in the Clinical Practice Guidelines and in the care of our patients with
T2DM.
Publisher
Bentham Science Publishers Ltd.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献